DRIO - DarioHealth Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.69
0.00 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.69
Open1.69
Bid0.00 x 100
Ask1.73 x 1000
Day's Range1.66 - 1.73
52 Week Range1.32 - 3.64
Volume28,548
Avg. Volume159,351
Market Cap27.852M
Beta0.02
PE Ratio (TTM)N/A
EPS (TTM)-1.66
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.17
Trade prices are not sourced from all markets
  • ACCESSWIRE18 days ago

    DarioHealth, New Glucose Monitoring System, Climbing Revenue, and Analysts Target

    NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • PR Newswire24 days ago

    DarioHealth Launches Customer Hotline to Pre-Order Its Apple iPhone Lightning-Compatible Glucose Monitor in the U.S.

    NEW YORK and CAESAREA, Israel, March 29, 2018 /PRNewswire/ --  DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, today announced it will offer its past and current subscription holders the option to pre-order its first Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System in the U.S. commencing on April 16, 2018. Subscription holders who are interested in ordering the new device will need to place their order through DarioHealth's special hotline for ordering: 1-888-665-7201. DarioHealth expects to ship its first iPhone Lightning-compatible glucose monitor in the coming weeks.

  • Business Wire26 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of DarioHealth Corp.

    Levi & Korsinsky announces it has commenced an investigation of DarioHealth Corp. concerning possible breaches of fiduciary duty. To obtain additional informat

  • MarketWatch27 days ago

    DarioHealth stock soars after iPhone-compatible glucose monitor receives FDA clearance

    Shares of DarioHealth Corp. are up 29% in premarket trading Monday after the company said it had received FDA clearance for its blood glucose monitoring system to be used on Apple Inc. iPhone 7, 8, and ...

  • DarioHealth Receives U.S. FDA Clearance for iPhone 7, 8 and iPhone X Smart Glucose Meter
    PR Newswire27 days ago

    DarioHealth Receives U.S. FDA Clearance for iPhone 7, 8 and iPhone X Smart Glucose Meter

    NEW YORK and CAESAREA, Israel, March 26, 2018 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, announced today that the United States Food and Drug Administration (FDA) has granted Pre-market Notification (510(k)) clearance for the Company's Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System which enables the use of the Dario app on iPhone 7, 8 and X smart mobile devices (SMD). Consumers in the U.S. market will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the iPhone X.

  • PR Newswirelast month

    DarioHealth Reports Fourth Quarter and Year End 2017 Results

    Record 4Q 2017 Revenue of $1.6 Million ; growth of 88% Record 2017 Revenue of $5.2 Million ; growth of 84% CAESAREA, Israel , March 19, 2018 /PRNewswire/ --   DarioHealth Corp. (NASDAQ: DRIO), a leading ...

  • Are Earnings Prospects Improving For Loss-Making DarioHealth Corp’s (NASDAQ:DRIO)?
    Simply Wall St.last month

    Are Earnings Prospects Improving For Loss-Making DarioHealth Corp’s (NASDAQ:DRIO)?

    For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...

  • ACCESSWIRElast month

    DarioHealth Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 19, 2018 / DarioHealth Corp. (NASDAQ: DRIO ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 19, 2018 at 9:00 AM Eastern Time. ...

  • DarioHealth Announces Revised Date for Fourth Quarter and Year End 2017 Conference Call
    PR Newswirelast month

    DarioHealth Announces Revised Date for Fourth Quarter and Year End 2017 Conference Call

    Earnings and Business Update Conference Call Now Scheduled for 9:00am EDT on Monday, March 19, 2018 NEW YORK and CAESAREA, Israel , March 14, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading ...

  • DarioHealth to Host Fourth Quarter and Year End 2017 Conference Call on March 20, 2018
    PR Newswirelast month

    DarioHealth to Host Fourth Quarter and Year End 2017 Conference Call on March 20, 2018

    Earnings and Business Update Conference Call Scheduled for 9:00am EDT NEW YORK and CAESAREA, Israel , March 8, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company ...

  • DarioHealth Presents Dario Engage Vision at the HIMSS Annual Conference & Exhibition
    PR Newswire2 months ago

    DarioHealth Presents Dario Engage Vision at the HIMSS Annual Conference & Exhibition

    LAS VEGAS, Mar 5, 2018 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, today announced it is sharing its Dario Engage vision of moving diabetes management to focus on personalization this week at the HIMSS (Healthcare Information and Management Systems Society) Annual Conference & Exhibition (Booth #10343). Dario Engage is expected to be a preeminent platform that is data and performance driven, which will support diabetes coaching services on a larger scale. Erez Raphael, Chairman and CEO of DarioHealth, commented, "HIMSS18 is the foremost event in our industry and a great stage to showcase Dario Engage, which is our next step in the DarioHealth story.

  • DarioHealth Launches Sales of Dario™ Blood Glucose Monitoring System on Amazon Prime
    PR Newswire2 months ago

    DarioHealth Launches Sales of Dario™ Blood Glucose Monitoring System on Amazon Prime

    NEW YORK and CAESAREA, Israel, Feb. 20, 2018 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, announced today the launch and first sales of its Dario™ Blood Glucose Monitoring System on Amazon. Distribution on Amazon strengthens DarioHealth's online retail presence, as it provides its users and potential clients with additional purchasing and shipping options, including shipping via Amazon Prime, as all fulfillment is being managed by Amazon. With over 300 million users, Amazon is one of the largest online retailers.

  • DarioHealth Partners With a Leading Diabetes Clinic
    PR Newswire2 months ago

    DarioHealth Partners With a Leading Diabetes Clinic

    NEW YORK and CAESAREA, Israel, Feb. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania, LLC, the clinical practice of Dr. Alan Schorr and Dr. Arvind Cavale, with expertise in incorporating state of the art technology in the treatment of people with Type 1 and Type 2 diabetes. With this market expansion, the Dario™ Blood Glucose Monitoring System will be offered in their clinic, which provides a wide-range of treatment therapies for over 5,000 patients. The product was chosen because it is compact, accurate, and it has the ability for users and healthcare practitioners to simplify diabetes management via a smartphone.

  • DarioHealth Wins Key Contract Ensuring Its Platform to be Utilized in Clinical Study
    PR Newswire2 months ago

    DarioHealth Wins Key Contract Ensuring Its Platform to be Utilized in Clinical Study

    NEW YORK and CAESAREA, Israel, Feb. 8, 2018 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing diabetes. The pharmaceutical company is seeking FDA clearance for this drug and has selected DarioHealth to run and track the blood glucose readings of participants in the clinical study.

  • GlobeNewswire3 months ago

    dynaCERT Appoints Colonel Yalon Farhi as Director, Provides Corporate Update Including Equity Financing and Note Redemption

    TORONTO, Jan. 31, 2018-- dynaCERT Inc. is pleased to announce the appointment of Colonel Yalon Farhi to its Board of Directors. Colonel Farhi is a colonel in the Israeli Defense Forces, serving since 1998. ...

  • DarioHealth Introduces iPhone 7, iPhone 8, and iPhone X Compatible Smart Glucose Meter to the Australian Market
    PR Newswire3 months ago

    DarioHealth Introduces iPhone 7, iPhone 8, and iPhone X Compatible Smart Glucose Meter to the Australian Market

    CAESAREA, Israel, Jan. 17, 2018 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has launched the Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System in the Australian market. The Lightning®-enabled device ensures that Apple consumers "Down Under" will be able to connect the Dario smart glucose meter to the latest iOS handsets, including the brand-new iPhone X.

  • DarioHealth Begins Selling iPhone 7, iPhone 8, and iPhone X Smart Glucose Meter in the U.K.
    PR Newswire3 months ago

    DarioHealth Begins Selling iPhone 7, iPhone 8, and iPhone X Smart Glucose Meter in the U.K.

    CAESAREA, Israel, Jan. 8, 2018 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, today announced it has successfully sold the first Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System in the United Kingdom, according to schedule. The Lightning®-enabled device ensures that consumers will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8 and iPhone X. Apple iOS has just over 50% market share in the U.K. With additional potential users, DarioHealth believes that it will be able to quickly increase U.K.-driven revenues and achieve greater market penetration. This news comes shortly after the company's recent announcement of receiving the Therapeutic Goods Administration (TGA) Mark in the Australian market for the same Lightning®-enabled device.  Sales of the device are expected to begin in Australia mid-January. DarioHealth expects to hear from the U.S. Food and Drug Administration (F.D.A.) about necessary clearance over the next few months.

  • What You Must Know About DarioHealth Corp’s (NASDAQ:DRIO) Major Investors
    Simply Wall St.4 months ago

    What You Must Know About DarioHealth Corp’s (NASDAQ:DRIO) Major Investors

    I am going to take a deep dive into DarioHealth Corp’s (NASDAQ:DRIO) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of a company’sRead More...

  • DarioHealth Granted Another U.S. Patent Strengthening its Core Technology
    PR Newswire4 months ago

    DarioHealth Granted Another U.S. Patent Strengthening its Core Technology

    Dror Bacher, COO and Vice President of R&D at DarioHealth, commented, "We are very excited to finish off 2017 with this news. This patent has already been part and parcel of the Dario Blood Glucose Monitoring System since it entered the U.S. market and showcases our commitment to further enhancing our core technologies on our native mobile solutions. "With this patent, DarioHealth strengthens its IP rights and enables us to be compatible with more devices.

  • PR Newswire4 months ago

    DarioHealth Gains Regulatory Approval in Australia for iPhone 7, iPhone 8, and iPhone X Smart Glucose Meter

    CAESAREA, Israel, Dec. 18, 2017 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that it received the Therapeutic Goods Administration (TGA) Mark for its Lightning®-enabled version of the acclaimed Dario™ Blood Glucose Monitoring System in Australia. The regulatory approval ensures that consumers in the Australian market will be able to receive the same quality user experience with DarioHealth on the latest Apple devices, including the brand-new iPhone 8 and iPhone X.

  • Does Zero-Debt Make DarioHealth Corp (DRIO) A Financially Strong Company?
    Simply Wall St.4 months ago

    Does Zero-Debt Make DarioHealth Corp (DRIO) A Financially Strong Company?

    DarioHealth Corp (NASDAQ:DRIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is DRIO willRead More...

  • Should You Be Content With DarioHealth Corp’s (DRIO) 55.7% Earnings Growth?
    Simply Wall St.5 months ago

    Should You Be Content With DarioHealth Corp’s (DRIO) 55.7% Earnings Growth?

    Today I will take a look at DarioHealth Corp’s (NASDAQ:DRIO) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past few years,Read More...

  • DarioHealth Corp. :DRIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube5 months ago

    DarioHealth Corp. :DRIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis DarioHealth Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of DarioHealth Corp. – Ionis Pharmaceuticals, Inc., Exact Sciences Corporation and Mateon Therapeutics, Inc. (IONS-US, EXAS-US and MATN-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)

  • DarioHealth Launches Version 3.5 of its MyDario App to Support iPhone 7 and iPhone 8
    PR Newswire5 months ago

    DarioHealth Launches Version 3.5 of its MyDario App to Support iPhone 7 and iPhone 8

    CAESAREA, Israel, Nov. 20, 2017 /PRNewswire/ -- DarioHealth Corp. (DRIO), a leading global digital health company with mobile health and big data solutions, today announced the availability of update version 3.5 of its MyDario app. The app update includes support for DarioHealth's new Lightning compatible device for iPhone 7 and iPhone 8 which was recently awarded the CE Mark. The DarioHealth lightning adapter is currently under consideration for regulatory approval with the United States Food and Drug Administration and the Therapeutic Goods Administration (TGA) in Australia.

  • What Can We Expect for DarioHealth Corp (DRIO) Moving Forward?
    Simply Wall St.5 months ago

    What Can We Expect for DarioHealth Corp (DRIO) Moving Forward?

    DarioHealth Corp (NASDAQ:DRIO), a USD$16.18M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as anRead More...